[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60234341D1 - Chinazoline derivative zur förderung der freisetzung von parathyroidmshormonen - Google Patents

Chinazoline derivative zur förderung der freisetzung von parathyroidmshormonen

Info

Publication number
DE60234341D1
DE60234341D1 DE60234341T DE60234341T DE60234341D1 DE 60234341 D1 DE60234341 D1 DE 60234341D1 DE 60234341 T DE60234341 T DE 60234341T DE 60234341 T DE60234341 T DE 60234341T DE 60234341 D1 DE60234341 D1 DE 60234341D1
Authority
DE
Germany
Prior art keywords
chinazoline
derivative
promote
release
parathyroid hormones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234341T
Other languages
English (en)
Inventor
Rene Beerli
Ruben Alberto Tommasi
Sven Weiler
Leo Widler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26246197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60234341(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0114701A external-priority patent/GB0114701D0/en
Priority claimed from GB0114702A external-priority patent/GB0114702D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60234341D1 publication Critical patent/DE60234341D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/88—Nicotinoylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60234341T 2001-06-15 2002-06-14 Chinazoline derivative zur förderung der freisetzung von parathyroidmshormonen Expired - Lifetime DE60234341D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0114701A GB0114701D0 (en) 2001-06-15 2001-06-15 Organic compounds
GB0114702A GB0114702D0 (en) 2001-06-15 2001-06-15 Organic compounds
PCT/EP2002/006606 WO2002102782A2 (en) 2001-06-15 2002-06-14 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE

Publications (1)

Publication Number Publication Date
DE60234341D1 true DE60234341D1 (de) 2009-12-24

Family

ID=26246197

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234341T Expired - Lifetime DE60234341D1 (de) 2001-06-15 2002-06-14 Chinazoline derivative zur förderung der freisetzung von parathyroidmshormonen

Country Status (31)

Country Link
US (1) US8476286B2 (de)
EP (2) EP1401451B1 (de)
JP (2) JP4118801B2 (de)
KR (1) KR100699959B1 (de)
CN (1) CN1516587A (de)
AR (1) AR038658A1 (de)
AT (1) ATE447958T1 (de)
AU (1) AU2002325242B2 (de)
BR (1) BR0210920A (de)
CA (1) CA2449234C (de)
CO (1) CO5550443A2 (de)
CY (1) CY1109767T1 (de)
CZ (1) CZ20033389A3 (de)
DE (1) DE60234341D1 (de)
DK (1) DK1401451T3 (de)
ES (1) ES2336197T3 (de)
HU (1) HUP0400205A3 (de)
IL (2) IL159000A0 (de)
MX (1) MXPA03011626A (de)
MY (1) MY145325A (de)
NO (1) NO326384B1 (de)
NZ (1) NZ529716A (de)
PE (1) PE20030121A1 (de)
PL (1) PL364474A1 (de)
PT (1) PT1401451E (de)
RU (1) RU2302244C2 (de)
SI (1) SI1401451T1 (de)
SK (1) SK287802B6 (de)
TW (1) TWI330179B (de)
WO (1) WO2002102782A2 (de)
ZA (1) ZA200309042B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
AU2007231842B2 (en) * 2002-12-23 2011-04-14 Novartis Ag Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone
EP2189439A3 (de) * 2003-04-23 2011-05-04 Japan Tobacco, Inc. CaSR-Antagonist
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
GB0511410D0 (en) * 2005-06-03 2005-07-13 James Black Foundation Benzotrizepinone derivatives
GB0516723D0 (en) * 2005-08-15 2005-09-21 Novartis Ag Organic compounds
GB0610018D0 (en) * 2006-05-19 2006-06-28 James Black Foundation Benzotriazepinone derivatives
KR100974081B1 (ko) * 2008-07-24 2010-08-04 이화여자대학교 산학협력단 착탈식 치아 교정기구
BRPI1008376B1 (pt) * 2009-02-10 2021-08-31 Janssen Pharmaceutica Nv Quinazolinonas como inibidores de prolil hidroxilase
TWI496782B (zh) 2009-04-28 2015-08-21 Chugai Pharmaceutical Co Ltd Spiro haloperidone derivatives
EP3091009B1 (de) 2011-10-25 2018-08-29 Janssen Pharmaceutica NV Megluminsalzformulierungen von 1-(5,6-dichlor-1h-benzo[d]imidazol-2-yl)-1h-pyrazol-4-carbonsäure
JP5951799B2 (ja) * 2012-12-10 2016-07-13 中外製薬株式会社 ヒダントイン誘導体
CN106572994B (zh) 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物
US20230257359A1 (en) * 2020-06-10 2023-08-17 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1313789A (en) * 1919-08-19 Puanookai h cu
US1353789A (en) * 1920-09-21 Window-venthiator
US1195066A (en) * 1916-08-15 Traction whxel
US1181570A (en) * 1911-03-18 1916-05-02 Churchward Internat Steel Company Alloyed steel.
US1046063A (en) * 1911-12-12 1912-12-03 Frederick H Felt Scale.
US1248428A (en) * 1917-06-26 1917-11-27 James Ferdinand Groom Roberts Cooking apparatus.
US3305553A (en) * 1965-10-18 1967-02-21 Parke Davis & Co 2-aminoquinazoline derivatives
CH487902A (de) * 1966-08-29 1970-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Chinazolinonen
FR6001M (de) 1966-12-02 1968-04-29
BG16442A3 (bg) 1967-10-30 1972-11-20 Max Denzer Метод за получаване на нови о-изопропиламинобензофенони
US3923803A (en) * 1968-07-18 1975-12-02 Sumitomo Chemical Co 2(1H)-Quinozalinones and process therefor
DE1935404C3 (de) 1968-07-18 1975-02-13 Sumitomo Chemical Co., Ltd., Osaka (Japan) Verfahren zur Herstellung von Chinazoline nen
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
DE2037693C3 (de) * 1969-08-02 1975-01-16 Sumitomo Chemical Co., Ltd., Osaka (Japan) 1-Cyclopropylmethyl-2(1 H)-chinazolinonderivate
US3767797A (en) * 1969-08-02 1973-10-23 Sumitomo Chemical Co Novel quinazolinone derivatives as antiinflammatory and analgesic agents
JPS5118423B1 (de) 1970-12-08 1976-06-09
JPS5013271B2 (de) 1971-10-04 1975-05-19
BE790804A (fr) * 1971-11-18 1973-04-30 Sandoz Sa Procede de preparation de derives de la quinazoline
US3812257A (en) * 1972-04-07 1974-05-21 Sumitomo Chemical Co Uricosuric agent
JPS5418269B2 (de) * 1972-07-20 1979-07-06
JPS555506B2 (de) * 1972-09-07 1980-02-07
US3997564A (en) * 1973-04-13 1976-12-14 Sandoz, Inc. N-(3,4-methylenedioxy-phenyl)ureas
US4067868A (en) 1973-04-17 1978-01-10 Sumitomo Chemical Company, Limited Production of quinazolinone compounds
JPS5046680A (de) 1973-08-20 1975-04-25
JPS518287A (en) 1974-07-13 1976-01-23 Sumitomo Chemical Co Kinazorinonjudotaioyobi sonoenno seizoho
JPS5125193A (en) * 1974-08-26 1976-03-01 Sumitomo Chemical Co Kinazorinjudotaino biryoteiryoho
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5271483A (en) * 1975-12-11 1977-06-14 Sumitomo Chem Co Ltd Synthesis of 2(1h)-quinazolinone derivatives
CH625512A5 (de) * 1976-12-13 1981-09-30 Sandoz Ag
US4171441A (en) * 1977-09-06 1979-10-16 Sandoz, Inc. Preparation of quinazolin-2(1H)-ones
JPS5795966A (en) 1980-12-04 1982-06-15 Sumitomo Chem Co Ltd Novel 2(1h)-quinazolinone derivative
TW232013B (de) 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
ATE188377T1 (de) * 1993-06-29 2000-01-15 Takeda Chemical Industries Ltd Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
CZ290670B6 (cs) * 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
US5773663A (en) * 1996-05-01 1998-06-30 American Cyanamid Company Fungicidal methods, compounds and compositions containing benzophenones
DE19524398C1 (de) * 1995-07-04 1996-11-21 Adalbert Gubo Verfahren zum Archivieren von Dokumenten
KR100331512B1 (ko) * 1995-08-22 2002-10-09 마쯔시다덴기산교 가부시키가이샤 광디스크장치,기록파워및소거파워의설정방법
US6008230A (en) * 1995-10-16 1999-12-28 Fujisawa Pharmaceutical Co., Ltd. Quinoline compounds as H+ -ATPases
CA2190708A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
EP1322636A1 (de) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. 6-(substituierte phenyl)methyl)chinolin- und chinazolinderivate und deren verwendung als farneyl transferase inhibitoren
JP4530552B2 (ja) * 2001-01-29 2010-08-25 富士通セミコンダクター株式会社 半導体装置及びその製造方法
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7776035B2 (en) * 2004-10-08 2010-08-17 Covidien Ag Cool-tip combined electrode introducer

Also Published As

Publication number Publication date
CA2449234A1 (en) 2002-12-27
EP2191832A1 (de) 2010-06-02
HUP0400205A3 (en) 2004-10-28
JP2008214349A (ja) 2008-09-18
BR0210920A (pt) 2008-04-08
ATE447958T1 (de) 2009-11-15
MXPA03011626A (es) 2004-04-05
JP2005502605A (ja) 2005-01-27
WO2002102782A2 (en) 2002-12-27
SK15212003A3 (sk) 2004-08-03
PE20030121A1 (es) 2003-04-02
CY1109767T1 (el) 2014-09-10
US20040180912A1 (en) 2004-09-16
NZ529716A (en) 2006-04-28
IL159000A0 (en) 2004-05-12
NO326384B1 (no) 2008-11-24
KR20040007702A (ko) 2004-01-24
MY145325A (en) 2012-01-31
NO20035573L (no) 2004-02-16
PT1401451E (pt) 2010-02-18
CN1516587A (zh) 2004-07-28
NO20035573D0 (no) 2003-12-12
DK1401451T3 (da) 2010-03-29
AR038658A1 (es) 2005-01-26
EP1401451B1 (de) 2009-11-11
CZ20033389A3 (cs) 2004-08-18
AU2002325242B2 (en) 2006-11-09
IL159000A (en) 2009-11-18
SK287802B6 (sk) 2011-10-04
CO5550443A2 (es) 2005-08-31
KR100699959B1 (ko) 2007-03-27
ES2336197T3 (es) 2010-04-09
CA2449234C (en) 2011-02-15
RU2302244C2 (ru) 2007-07-10
TWI330179B (en) 2010-09-11
RU2003137571A (ru) 2005-05-10
HUP0400205A2 (hu) 2004-07-28
WO2002102782A3 (en) 2003-05-01
ZA200309042B (en) 2004-05-21
PL364474A1 (en) 2004-12-13
EP1401451A2 (de) 2004-03-31
US8476286B2 (en) 2013-07-02
JP4118801B2 (ja) 2008-07-16
SI1401451T1 (sl) 2010-03-31

Similar Documents

Publication Publication Date Title
ATE354360T1 (de) Amidoacetonitrile zur bekämpfung von endoparasiten
NO20034836L (no) Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF)
ATE319426T1 (de) Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DE60234341D1 (de) Chinazoline derivative zur förderung der freisetzung von parathyroidmshormonen
DE60204857D1 (de) Flüssigkeitszerstäuber
DK1661563T3 (da) Forbindelser der påvirker ghicokinase
DE60201799D1 (de) Lösbares Befestigungsclip
DE60321722D1 (de) Derivate von aryl-chinazolin/aryl-2amino-phenyl-methanon zurförderung der freisetzung von parathormon
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DE50302818D1 (de) Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
DE602004012925D1 (de) Protokoll zur Erbringung von Diensten
ATE365455T1 (de) Aminoacetonitril-verbindungen zur bekämpfung von endoparasiten
IS7407A (is) Afleysing lausnarsambanda atorvastatínhálfkalsíums
FR2847629B1 (fr) Frein electromagnetique
DE50214155D1 (de) Ausrücklager
DE60007360D1 (de) Amorphe modifikation von torasemid
DE60327426D1 (de) Markierung von substraten
DE60235470D1 (de) N-heterocyclische inhibitoren der expression von tnf-alpha
ATE435022T1 (de) Mässigung der wirkung von endotoxinen
ATA14382002A (de) Formkörper zur vorbereitung von installationen
UA5714S (uk) Комплект етикеток
UA5777S (uk) Комплект етикеток
UA5775S (uk) Комплект етикеток
UA5149S (uk) Комплект етикеток

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN